About: Evaxion A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of advanced melanoma; EVX-03, DNA-based cancer vaccine for the treatment of solid tumors; and EVX-04, a therapeutic cancer vaccine candidate, which is in phase 1 trial for acute myeloid leukemia. Its programs also include vaccines that are in pre-clinical stage, which includes EVX-B1, a multi-component prophylactic vaccine targeting skin and soft tissue infections with S. aureus bacteria; EVX-B2 to target multi-component prophylactic vaccine against gonorrhea bacteria; EVX-B3 to target bacterial pathogen associated with repeated infections; and EVX-V1, a multi-component prophylactic vaccine candidate for cytomegalovirus. The company was formerly known as Evaxion Biotech A/S and changed its name to Evaxion A/S in May 2025. Evaxion A/S was incorporated in 2008 and is based in Horsholm, Denmark.
Sector: Healthcare
Industry: Biotechnology
Latest price: $3.01 (-1.95%)
EVAX NASDAQ Evaxion Biotech AS
Evaxion Biotech AS share price
EVAX price activity
Last Price
$3.010
Change (24hr)
-0.06 USD (-1.95%)
Volume
43.76K
Volume (4w avg)
-
Open
$3.23
Day Range
$3.01 - $3.23
Previous Close
$3.07
Last Trade
12 Oct, 3:35 pm GMT+0
Delayed
12 Oct, 3:35 pm GMT+0
EVAX price performance
Delayed
12 Oct, 3:35 pm GMT+0
EVAX Market Signals